

TUMOUR-INFORMED, ULTRA-SENSITIVE CTDNA ANALYSIS

# See cancer come back before a scan can.

A liquid-biopsy assay built from each patient's own tumour, so you detect minute traces of circulating tumour DNA, follow them over time, and act on what treatment is really doing. One blood draw, processed entirely within the EU.

**Ultra-sensitive**  
Detection to very low VAF

**Patient-specific**  
Personalised panel

**Persistent monitoring**  
Track over time

**WHAT YOU USE IT FOR**

- Early recurrence detection**  
Flag relapse months before imaging
- Minimal residual disease (MRD) monitoring**  
Confirm whether disease persists after treatment
- Treatment response assessment**  
See if therapy is working, sooner

**WHY TUMOUR-INFORMED**

**↑ TUMOUR-INFORMED**

- Greater sensitivity
- Full mutation spectrum
- Reduced bias

**↓ TUMOUR-NAIVE**

- Lower sensitivity
- Limited scope
- Potential bias

**HOW IT WORKS · EU-BASED, END TO END**

**Tumour + control**  
FFPE / fresh frozen, plus whole blood

**Exome sequencing**  
Mutational profile

**Smart personalised panel**  
Up to 50 patient-specific assays

**Plasma samples**  
Longitudinal liquid biopsy

**SiMSen-Seq**  
Ultrasensitive analysis & report

**3-4 wks** **Set up the patient**  
Personalised panel design, mean time

**4-7 days** **Each ctDNA result**  
Working days, per plasma timepoint

**Every report:** ctDNA load (MM/mL and VAF), per-variant molecule counts, clonal-evolution tracking, and full raw data via secure transfer.

**WORK WITH US YOUR WAY**

**Full-service ctDNA**  
We run the complete workflow and reporting.

**Personalised panels in-house**  
Custom panels run on your own sequencer.

**Fast to adopt.** No need to build tumour-informed assays or bioinformatics from scratch.

**WHAT SETS US APART**

- Flexible inputs**  
Biopsies, WES / WGS, large-panel data
- Rapid turnaround**  
ctDNA results in 4 to 7 working days
- EU-based, GDPR**  
All work performed within the EU

- Tailored reports**  
Bespoke, actionable insight
- Clinically relevant**  
Add resistance markers in one assay
- Built to scale**  
From single cases to trial cohorts

